Neb. Rev. Stat. §§ 71-9607
Current with changes through the 2024 First Special Legislative Session
If an eligible patient dies while being treated by an investigational drug, biological product, or device, the manufacturer may not seek reimbursement for any outstanding debt related to the treatment or lack of insurance due to the treatment from the eligible patient's or his or her caretaker's estate.
Neb. Rev. Stat. §§ 71-9607